Tonix Pharmaceuticals Holding Corp. (TNXP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Tonix Pharmaceuticals reported revenue of $13.1M, up 29.8% from $10.1M the year before. Net income was -$124.0M (a -946.2% net margin), or -$14.57 per diluted share. Gross margin was 49.3% and operating margin was -959.1%. Operating activities generated -$99.8M of cash, leaving -$103.2M of free cash flow. At fiscal year end, Tonix Pharmaceuticals held $277.2M in total assets against $32.0M in total liabilities, including $207.6M of cash and equivalents.
Open the full interactive Tonix Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Tonix Pharmaceuticals Key Stats
| Share Price | $6.13 |
|---|---|
| Market Cap | $102.0M |
| Revenue YoY Growth | +29.8% |
| 52-Week Range | $6.13 – $20.35 |
| Shares Outstanding | 16.6 million (basic, 2026 Q2) |
Tonix Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7.8M | $10.1M | $13.1M |
| Cost of Goods Sold | $50.5M | $92.3M | $112.1M | $126.1M | $146.8M | $138.8M |
| Gross Profit | -$50.5M | -$92.3M | -$112.1M | $3.0M | $2.3M | $6.5M |
| Operating Income | -$50.5M | -$92.3M | -$112.1M | -$118.4M | -$136.7M | -$125.7M |
| Pre-Tax Income | -$50.5M | -$92.3M | -$110.2M | -$116.7M | -$130.0M | -$124.0M |
| Net Income | -$50.5M | -$92.3M | -$110.2M | -$116.7M | -$130.0M | -$124.0M |
| Diluted EPS | -$352000.00 | -$166400.00 | -$65400.00 | -$21920.00 | -$176.60 | -$14.57 |
Tonix Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.3M | $5.4M | $6.9M | $13.5M |
| Net Income | -$32.0M | -$46.9M | -$40.2M | -$40.6M |
| Diluted EPS | -$3.59 | -$5.51 | -$2.93 | -$2.44 |
Tonix Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.1M | $178.7M | $120.2M | $24.9M | $98.8M | $207.6M |
| Current Assets | $88.0M | $189.0M | $130.8M | $47.8M | $119.0M | $228.9M |
| Total Assets | $98.2M | $240.9M | $225.7M | $154.5M | $162.9M | $277.2M |
| Current Liabilities | $9.8M | $21.7M | $18.2M | $18.9M | $18.3M | $30.8M |
| Total Long-Term Debt | — | — | — | $8.9M | $7.5M | — |
| Total Liabilities | $10.5M | $22.2M | $18.5M | $48.9M | $23.3M | $32.0M |
| Shareholders' Equity | $87.6M | $218.7M | $207.2M | $105.5M | $139.6M | $245.2M |
Tonix Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$48.6M | -$75.6M | -$98.1M | -$102.0M | -$60.9M | -$99.8M |
| Cash From Investing | -$8.6M | -$35.3M | -$48.1M | -$29.1M | -$120,000 | -$4.5M |
| Cash From Financing | $123.1M | $212.5M | $87.8M | $36.5M | $134.9M | $214.5M |
| Free Cash Flow | -$57.1M | -$110.9M | -$146.2M | -$109.9M | -$61.0M | -$103.2M |
Figures from Tonix Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tonix Pharmaceuticals financials page for every line item.
Tonix Pharmaceuticals Company Profile
| Ticker | TNXP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Berkeley Heights, New Jersey |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001430306 |
Frequently Asked Questions
What was Tonix Pharmaceuticals' revenue in fiscal 2025?
Tonix Pharmaceuticals (TNXP) reported revenue of $13.1M for fiscal 2025.
What is Tonix Pharmaceuticals' annual revenue history?
Tonix Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $7.8M; 2024: $10.1M; 2025: $13.1M.
What was Tonix Pharmaceuticals' net income in fiscal 2025?
Tonix Pharmaceuticals reported net income of -$124.0M for fiscal 2025.
What was Tonix Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Tonix Pharmaceuticals' diluted EPS was -$14.57 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tonix Pharmaceuticals generate in fiscal 2025?
Tonix Pharmaceuticals generated -$103.2M of free cash flow in fiscal 2025.
What was Tonix Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Tonix Pharmaceuticals reported revenue of $13.5M.
How many shares of Tonix Pharmaceuticals are outstanding?
Tonix Pharmaceuticals reported a weighted average of 16.6 million basic shares outstanding in 2026 Q2.
What is Tonix Pharmaceuticals' market cap?
Based on its latest closing price, Tonix Pharmaceuticals (TNXP) has a market capitalization of about $102.0M.
When does Tonix Pharmaceuticals' fiscal year end?
Tonix Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Tonix Pharmaceuticals headquartered?
Tonix Pharmaceuticals lists its business address in Berkeley Heights, New Jersey in its SEC filings.